Title:
NFATc1 EXPRESSION INHIBITOR, OSTEOCLAST DIFFERENTIATION OR ACTIVATION INHIBITOR, AND PHARMACEUTICAL COMPOSITION
Document Type and Number:
WIPO Patent Application WO/2006/022234
Kind Code:
A1
Abstract:
[PROBLEMS] To provide an inhibitor capable of inhibiting any expression of NFATc1; a differentiation inhibitor capable of inhibiting any differentiation of osteoclast attributed to the expression of NFATc1, or an activation inhibitor capable of inhibiting any activation thereof; and a remedial composition capable of remedy of diseases attributed to the expression of NFATc1. [MEANS FOR SOLVING PROBLEMS] The compound of the formula: (1) (wherein R1 is a hydrogen atom or C2-C4 alkanoyl) is capable of inhibiting any expression of NFATc1. Consequently, substances comprising as an active ingredient the compound of the above formula (1) or a pharmacologically acceptable salt thereof are capable of inhibiting any differentiation or activation of osteoclast attributed to the expression of NFATc1 and are capable of remedy of diseases attributed to the expression of NFATc1.
More Like This:
| JP2007538106 | N-Cyclic Sulfonamide Inhibitor of γ-Secretase |
| JP2018008893 | HYPERGLYCEMIA INHIBITOR |
| WO/2021/102569 | CANNABINOID DERIVATIVES |
Inventors:
UMEZAWA KAZUO (JP)
TAKATSUNA HIROSHI (JP)
TAKATSUNA HIROSHI (JP)
Application Number:
PCT/JP2005/015223
Publication Date:
March 02, 2006
Filing Date:
August 22, 2005
Export Citation:
Assignee:
SIGNAL CREATION INC (JP)
UMEZAWA KAZUO (JP)
TAKATSUNA HIROSHI (JP)
UMEZAWA KAZUO (JP)
TAKATSUNA HIROSHI (JP)
International Classes:
A61K31/336; A61P19/08; A61P19/10; A61P29/00; A61P35/00; A61P35/04; A61P43/00
Domestic Patent References:
| WO2003103654A1 | 2003-12-18 |
Foreign References:
| JP2004154132A | 2004-06-03 |
Other References:
MATSUMOTO N ET AL: "Synthesis of NF-kappaB activation inhibitors derived from epoxyquinomicin C.", BIOORGANIC & MEDICINAL CHEMISTRY., vol. 10, 2000, pages 865 - 869, XP002934325
CLOHISY JC ET AL: "NF-kB signaling blockade abolishes implant particle-induced osteoclastogenesis.", JOURNAL OF ORTHOPAEDIC RESEARCH., vol. 22, January 2004 (2004-01-01), pages 13 - 20, XP004722545
LEE ZH ET AL: "Signal transduction by receptor activator of nuclear factor kappa B in osteoclasts.", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS., vol. 305, 2003, pages 211 - 214, XP002994025
TAKAYANAGI H ET AL: "Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts.", DEVELOPMENTAL CELL., vol. 3, 2002, pages 889 - 901, XP002994026
CLOHISY JC ET AL: "NF-kB signaling blockade abolishes implant particle-induced osteoclastogenesis.", JOURNAL OF ORTHOPAEDIC RESEARCH., vol. 22, January 2004 (2004-01-01), pages 13 - 20, XP004722545
LEE ZH ET AL: "Signal transduction by receptor activator of nuclear factor kappa B in osteoclasts.", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS., vol. 305, 2003, pages 211 - 214, XP002994025
TAKAYANAGI H ET AL: "Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts.", DEVELOPMENTAL CELL., vol. 3, 2002, pages 889 - 901, XP002994026
Attorney, Agent or Firm:
ISSHIKI & CO. (12-7 Shinbashi 2-chom, Minato-ku Tokyo 04, JP)
Download PDF: